Venglustat, Ibiglustat


Venglustat, Ibiglustat
CAS 1401090-53-6
C20H24FN3O2S, 389.5 g/mol
CAS 1629063-78-0, Ibiglustat L-malate, Venglustat malate, C24H30FN3O7S, 523.6 g/mol
Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate
[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate
- [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate
- Carbamic acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3S)-1-azabicyclo(2.2.2)oct-3-yl ester
- (1S,3R,4S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
- (S)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate
- (S)-Quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
- [(3S)-quinuclidin-3-yl] N-[1-[2-(4-fluorophenyl)thiazol-4-yl]-1-methyl-ethyl]carbamate
To treat the neurological symptoms of Type 3 Gaucher disease
Venglustat, sold under the brand name Infilbray, is a medication used for the treatment of Gaucher disease.[1] It is a glucosylceramide synthase inhibitor.[1] It is used as the salt venglustat malate.[1] It is given by mouth.[1]
The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]
Venglustat was approved for medical use in the United States in November 2026.[2]
Medical uses
Venglustat indicated for the treatment of neurological manifestations of type 3 Gaucher disease in people weighing at least 15 kg (33 lb).[1]
Venglustat crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.[2]
Type 3 Gaucher disease is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids, due to a deficient or malfunctioning enzyme.[2]
Adverse effects
The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]
Serious psychiatric risks, including suicidal ideation and behavior, have been reported.[2] Potential risks identified from animal studies include potential clouding of vision in younger people and adverse effects on fetal development when it is taken during pregnancy.[2]
History
The US Food and Drug Administration approved venglustat supported by data from a randomized, double-blind, multi-center clinical study enrolling 43 participants aged 12 years and older with type 3 Gaucher disease who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization.[2] Participants received either venglustat orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks.[2] Treatment effectiveness was evaluated using two assessments that capture the neurological symptoms central to daily life in participants with type 3 Gaucher disease, including those related to ataxia (loss of muscle control and coordination) and cognitive function.[2] At Week 52, participants treated with venglustat demonstrated improvement on a measure that combined both assessments compared to those taking enzyme replacement therapy for the treatment of non-neurologic manifestations of type 3 Gaucher disease.[2]
Society and culture
Legal status
Venglustat was approved for medical use in the United States in November 2026.[3]
The US Food and Drug Administration (FDA) granted the application for venglustat, breakthrough therapy, rare pediatric disease, fast track, orphan drug, and priority review designations.[2][3] The FDA granted the approval of Infilbray to Genzyme Corporation.[2]
Names
Venglustat is the international nonproprietary name.[4]
Venglustat is sold under the brand name Infilbray.[2][3]
SYN

SYN
WO2020/163244, 2020,
Organic Process Research and Development, 2015, vol. 19, V 5, PG 576 – 581
Journal of Medicinal Chemistry, 2023, vol. 66, V 2, PG1601 – 1615
PAT
WO2012129084 – GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012129084&_cid=P12-MWR8EI-85348-1

ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

……
References
- “Infilbray FDA label” (PDF). products.sanofi.us.
- “FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease” (Press release). FDA. 18 November 2026. Retrieved 19 November 2026.
This article incorporates text from this source, which is in the public domain. - “Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease”. Sanofi (Press release). 18 November 2026. Retrieved 19 November 2026.
- World Health Organization (2016). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76”. WHO Drug Information. 30 (3). hdl:10665/331020.
Further reading
- Bhattiprolu M, Kappler M, Han TU, Henderson M, Serlin Y, Sidransky E (May 2026). “Pharmacotherapies for Gaucher disease: what’s new on the horizon?”. Expert Opinion on Pharmacotherapy. 27 (7): 585–597. doi:10.1080/14656566.2026.2667325. PMID 42153355.
External links
- “Venglustat ( Code – C152852 )”. EVS Explore.
- “Venglustat Malate ( Code – C171783 )”. EVS Explore.
- Clinical trial number NCT05222906 for “Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)” at ClinicalTrials.gov
| Clinical data | |
|---|---|
| Trade names | Infilbray |
| AHFS/Drugs.com | Infilbray |
| License data | US DailyMed: Venglustat |
| Routes of administration | By mouth |
| Drug class | Glucosylceramide synthase inhibitor |
| ATC code | None |
| Legal status | |
| Legal status | US: ℞-only[1] |
| Identifiers | |
| IUPAC name | |
| CAS Number | 1401090-53-61629063-78-0 |
| PubChem CID | 6019924260199241 |
| IUPHAR/BPS | 11550 |
| DrugBank | DB14966 |
| ChemSpider | 34989426 |
| UNII | BLP1XA3FZA94855LQZ8D |
| KEGG | D11633D11634 |
| ChEBI | CHEBI:757083 |
| ChEMBL | ChEMBL4297611ChEMBL4594270 |
| PDB ligand | KYF (PDBe, RCSB PDB) |
| Chemical and physical data | |
| Formula | C20H24FN3O2S |
| Molar mass | 389.49 g·mol−1 |
| 3D model (JSmol) | Interactive imageInteractive image |
| SMILES | |
| InChI | |
PAT
- GLYCOSYLCERAMIDE SYNTHASE INHIBITORSPublication Number:BR-112013023774-B1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:EP-4559918-A2Priority Date:2011-03-18
- GLUCOSILCERAMIDE SINTASA INHIBITORS.Publication Number:MX-2013010710-APriority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:TW-I546301-BPriority Date:2011-03-18Grant Date:2016-08-21
- Glucosylceramide synthase inhibitorsPublication Number:KR-20140092239-APriority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2014255381-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2016207933-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:ES-2774293-T3Priority Date:2011-03-18Grant Date:2020-07-20
- Glucosylceramide synthase inhibitorsPublication Number:EP-3673906-B1Priority Date:2011-03-18Grant Date:2025-05-14
- GLYCOSYLCERAMIDE SYNTHASE INHIBITORSPublication Number:BR-122019017719-B1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:SG-193532-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2014255381-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2016207933-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:AU-2016244305-B2Priority Date:2011-03-18Grant Date:2018-05-24
- Glucosylceramide synthase inhibitorsPublication Number:AU-2016244305-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:AU-2012231275-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2020048266-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-9139580-B2Priority Date:2011-03-18Grant Date:2015-09-22
////////venglustat, ANAX LABS, Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate
#venglustat, #ANAX LABS, #Infilbray, #APPROVALS 2026, #FDA 2026, #Genz-682452, #GZ/SAR402671, #BLP1XA3FZA, #SAR-402671, #SAR 402671, #Genz-682452-AA, #BLP1XA3FZA, #GZ402671, #WHO 10063, #Ibiglustat L-malate, #Venglustat malate
Adrabetadex


Adrabetadex
CAS128446-35-5
MF C54H94O38, MW
1351.3 g/mol
APPROVALS 2026, FDA 2026, Lembaz, 8W6Q67R6NX, KLEPTOSE HPB, VT-270, VTS270, VTS-270, Niemann–Pick disease type C,
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2)
HYDROXYPROPYL BETADEX (0.6 HYDROXYPROPYL RESIDUES PER GLUCOSE)
(1S,3R,5R,6S,8R,10R,11S,13S,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,47R,48S,49R)-5,20,30,35-tetrakis(hydroxymethyl)-49-(2-hydroxypropoxy)-10,15,25-tris(2-hydroxypropoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,47,48-dodecol
To treat a severe form of Niemann-Pick disease type C
PAT
- CONCENTRATED LIQUID COMPOSITION OF THYROID HORMONE.Publication Number:ES-2369296-T3Priority Date:2006-01-06Grant Date:2011-11-29
- Concentrated liquid thyroid hormone compositionPublication Number:US-8318712-B2Priority Date:2006-01-06Grant Date:2012-11-27
- Concentrated liquid thyroid hormone compositionPublication Number:JP-5173832-B2Priority Date:2006-01-06Grant Date:2013-04-03
- Concentrated liquid thyroid hormone compositionPublication Number:WO-2007077252-A1Priority Date:2006-01-06
- Concentrated liquid thyroid hormone compositionPublication Number:JP-2009522335-APriority Date:2006-01-06
- Concentrated liquid thyroid hormone compositionPublication Number:CA-2634993-A1Priority Date:2006-01-06
- Concentrated Liquid Thyroid Hormone CompositionPublication Number:US-2009270507-A1Priority Date:2006-01-06
- Concentrated liquid thyroid hormone compositionPublication Number:KR-20080083685-APriority Date:2006-01-06
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

……
///////////adrabetadex, anax labs, APPROVALS 2026, FDA 2026, Lembaz, 8W6Q67R6NX, KLEPTOSE HPB, VT-270, VTS270, VTS-270, Niemann–Pick disease type C,
#adrabetadex, #anax labs, #APPROVALS 2026, #FDA 2026, #Lembaz, #8W6Q67R6NX, #KLEPTOSE HPB, #VT-270, #VTS270, #VTS-270, #Niemann–Pick disease type C,
Giredestrant

Giredestrant
CAS 1953133-47-5
MF C27H31F5N4O MW 522.6 g/mol
3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol
- 3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol
- (1R,3R)-1-[2,6-Difluoro-4-[[1-(3-fluoropropyl)-3-azetidinyl]amino]phenyl]-beta,beta-difluoro-1,3,4,9-tetrahydro-3-methyl-2H-pyrido[3,4-b]indole-2-propanol
Wilserdly, FDA 2026, APPROVALS 2026, GDC 9545, RG 6171, RO 7197597, 28P3DU6DB3
To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting
Giredestrant is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
Giredestrant, sold under the brand name Wilserdly, is an oral selective estrogen receptor degrader (SERD) used for the treatment of estrogen receptor-positive (ER+) breast cancer.[1][2] It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency.[1][3] Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein.[1][4][5]
Research
In clinical trials, giredestrant has been evaluated in patients with ER+breast cancer , including those with ESR1 mutations, both as a single agent and in combination with other therapies.[2][6] Its orally bioavailable.[3][4]
SCHEME

PAT
WO2016097072 – TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
F HOFFMANN LA ROCHE – WO2016/97072, 2016, A1, https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016097072&_cid=P22-MWMY5D-43733-1
PAT
US20160175289 – Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
https://patentscope.wipo.int/search/en/detail.jsf?docId=US174233194&_cid=P22-MWMXSA-28614-1
SYN
Journal of Medicinal Chemistry, 2021, vol. 64, # 16, p. 11841 – 11856

SYN
https://www.sciencedirect.com/org/science/article/abs/pii/S1083616022002432
Organic Process Research & Development, Date: 18 March 2022, Pages: 568-582 Volume: Volume 26, Issue 3
GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2– breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C–N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet–Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.

PATENTS
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:US-12233052-B2Priority Date:2014-12-18Grant Date:2025-02-25
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:EP-3760623-A1Priority Date:2014-12-18
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:TW-I784255-BPriority Date:2014-12-18Grant Date:2022-11-21
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:US-9980947-B2Priority Date:2014-12-18Grant Date:2018-05-29
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:TW-I699363-BPriority Date:2014-12-18Grant Date:2020-07-21
- Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereofPublication Number:EP-3233852-B1Priority Date:2014-12-18Grant Date:2020-07-15
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:US-2025114338-A1Priority Date:2014-12-18
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:JP-7446348-B2Priority Date:2014-12-18Grant Date:2024-03-08
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:US-2016175289-A1Priority Date:2014-12-18
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

| Clinical data | |
|---|---|
| Trade names | Wilserdly |
| Other names | GDC-9545, RG6171, RO7197597 |
| Identifiers | |
| IUPAC name | |
| CAS Number | 1953133-47-5 |
| PubChem CID | 121410806 |
| ChemSpider | 103748880 |
| UNII | 28P3DU6DB3 |
| KEGG | D11961 |
| ChEMBL | ChEMBL4650316 |
| Chemical and physical data | |
| Formula | C27H31F5N4O |
| Molar mass | 522.564 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
References
- “Giredestrant (GDC-9545)”. Cancer.gov. U.S. National Cancer Institute. 14 November 2024.
- Malhi V, Agarwal P, Gates MR, Liu L, Wang J, De Bruyn T, et al. (December 2023). “Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer”. Cancer Research Communications. 3 (12): 2551–2559. doi:10.1158/2767-9764.CRC-23-0324. PMC 10722959. PMID 38019116.
- “A clinical study to compare giredestrant with fulvestrant, both combined with a targeted therapy (CDK4/6 inhibitor) in people with ER-positive, HER2-negative breast cancer that has come back after adjuvant hormone therapy”. Roche.
- Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, et al. (February 2024). “Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer”. Clinical Cancer Research. 30 (4): 754–766. doi:10.1158/1078-0432.CCR-23-1796. PMC 10870118. PMID 37921755.
- Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, et al. (August 2021). “GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer”. Journal of Medicinal Chemistry. 64 (16): 11841–11856. doi:10.1021/acs.jmedchem.1c00847. PMID 34251202.
- Lawrence L (25 July 2024). “Giredestrant Bests Anastrozole in ER+, HER2- Early Breast Cancer”.
Further reading
- Gheysen M, Punie K, Wildiers H, Neven P (November 2024). “Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review”. Cancer Treatment Reviews. 130 102825. doi:10.1016/j.ctrv.2024.102825. PMID 39293125.
- Guglielmi G, Del Re M, Gol LS, Bengala C, Danesi R, Fogli S (April 2024). “Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer”. European Journal of Pharmacology. 969 176424. doi:10.1016/j.ejphar.2024.176424. hdl:2434/1128718. PMID 38402929.
- Garcia-Fructuoso I, Gomez-Bravo R, Schettini F (November 2022). “Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment”. Current Opinion in Oncology. 34 (6): 635–642. doi:10.1097/CCO.0000000000000892. PMID 36000362.
- Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, et al. (June 2022). “Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer”. Expert Opinion on Investigational Drugs. 31 (6): 515–529. doi:10.1080/13543784.2021.1983542. PMID 34694932.
- Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. (June 2024). “Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study”. Journal of Clinical Oncology. 42 (18): 2149–2160. doi:10.1200/JCO.23.01500. PMC 11185917. PMID 38537155.
/////////////Giredestrant, ANAX LABS, GDC 9545, RG 6171, RO 7197597, Wilserdly, FDA 2026, APPROVALS 2026, GDC-9545, RG6171, RO7197597, 28P3DU6DB3, breast cancer
#Giredestrant, #ANAX LABS, #GDC 9545, #RG 6171, #RO 7197597, #Wilserdly, #FDA 2026, #APPROVALS 2026, #GDC-9545, #RG6171, #RO7197597, #28P3DU6DB3, #breast cancer
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO














